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Abstract
Background and Aims: During fibrogenesis, in which excessive remodeling of the extracellular matrix occurs, both the
quantity of type VI collagen and levels of matrix metalloproteinases, including MMP-2 and MMP-9, increase significantly.
Proteolytic degradation of type VI collagen into small fragments, so-called neo-epitopes, may be specific biochemical
marker of liver fibrosis. The aim of this study was to develop an ELISA detecting a fragment of type VI collagen generated by
MMP-2 and MMP-9, and evaluate this assay in two preclinical models of liver fibrosis.
Methods: Mass spectrometric analysis of cleaved type VI collagen revealed a large number of protease-generated neo-
epitopes. A fragment unique to type VI collagen generated by MMP-2 and MMP-9 was selected for ELISA development. The
CO6-MMP assay was evaluated in two rat models of liver fibrosis: bile duct ligation (BDL) and carbon tetrachloride (CCl4)-
treated rats.
Results: Intra- and inter-assay variation was 4.1% and 10.1% respectively. CO6-MMP levels were significantly elevated in
CCl4-treated rats compared to vehicle-treated rats at weeks 12 (mean 30.9 ng/mL vs. 12.8 ng/mL, p = 0.002); week 16 (mean
34.0 ng/mL vs. 13.7 ng/mL, p = 0.0018); and week 20 (mean 35.3 ng/mL vs. 13.3 ng/mL, p = 0.0033) with a tight correlation
between hepatic collagen content and serum levels of CO6-MMP (R2 = 0.58, p,0.0001) in CCl4- treated rats. In BDL rats,
serum levels of CO6-MMP were significantly elevated compared to the levels in sham-operated animals both at 2 weeks
(mean 29.5 ng/mL vs. 14.2 ng/mL, p = 0.0001) and 4 weeks (mean 33.0 ng/mLvs. 11.8 ng/mL, p = 0.0003).
Conclusions: This novel ELISA is the first assay enabling assessment of MMP degraded type VI collagen, allowing
quantification of type VI collagen degradation, which would be relevant for different pathologies. The marker was highly
associated with liver fibrosis in two liver fibrosis animal models, suggesting type VI turnover to be a central player in
fibrogenesis.
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Introduction
Liver fibrosis due to viral or alcohol-induced injury is one of the
leading causes of death worldwide [1]. To date no curative
treatment for liver fibrosis is available and patients are dependent
on the success of inactivation or removal of the injurious agent or
in the case of end-stage cirrhosis, on liver transplantation.
Assessment of liver fibrosis is important to estimate the prognosis
for the progression to liver cirrhosis and to determine surveillance
strategies. At present, liver biopsy is the most commonly used
method for fibrosis assessment, but it is invasive, associated with
patient discomfort and, in rare cases, with serious complications
[2]. In addition, the accuracy of liver biopsy is limited due to
sampling error and significant intra- and inter-observer variability
in histological staging [3,4]. Therefore, research has focused on
the evaluation of non-invasive methods for the assessment of liver
fibrosis [5].
Fibrosis may be described as extensive scar formation, observed
as increased deposition and abnormal distribution of extracellular
matrix (ECM) components such as collagens and proteoglycans.
ECM remodeling is a key process of tissue homoeostasis [6–8], and
specific proteolytic activities are a prerequisite for a range of
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cellular functions and interactions during the process [9]. The specific
proteolytic activities are precisely coordinated under physiological
situations, with a specified sequence of events resulting in controlled
tissue turnover. In pathological situations, including inflammations,
fibrosis and cancer, the normal damage/repair balance is displaced
[10], leading to excessive remodeling. As a consequence of this tissue
turnover, there is a release of several protein degradation fragments
specific for the combination of the involved proteases, the affected
organ and the disease. The fragmentation results in exposure of new
peptide ends (so-called neo-epitopes) to which specific antibodies can
be developed. These neo-epitopes may be used for the design of
molecular biochemical markers [11].
Endopeptidases such as metalloproteinases (MMPs) play a major
part in the degradation of extracellular macromolecules such as
collagens and during fibrogenesis the levels of MMPs increase
[12,13]. With respect to excessive proteolytic activity in the fibrous
tissue, the gelatinases MMP-2 and MMP-9 have been investigated
and documented to be highly regulated [12,13]. Type VI collagen
degradation yields several unique fragments, including the CO6-
MMP fragment (YRGPEGPQGP). The combination of active and
over-expressedMMPs and increased levels of type VI collagen poses
the interesting hypothesis that a MMP-generated fragment of type
VI collagen could be used as a biomarker of liver fibrosis.
Type VI collagen is a ubiquitous ECM protein. It is a
heterotrimer composed of three different a-chains with short triple
helical domains [14]. Following secretion into the ECM, type VI
collagen tetramers aggregate into filaments and form an indepen-
dent microfibrillar network in virtually all connective tissues, except
for bone [15]. Type VI collagen has been identified within most
tissues and it is generally accepted that it plays a role in the
maintenance of tissue integrity since it participates in both cell-
matrix and matrix-matrix interactions [16]. Type VI collagen
interacta with many other ECM proteins, including fibronectin
[17], type IV collagen [18], decorin, biglycan and type II collagen
[19]. In close association with other collagen types, type VI collagen
forms filaments and has therefore been described as a connecting
protein [14,20]. It is mainly found in a pericellular localization
around a number of cell types – in the liver, mainly around hepatic
stellate cells and around hepatocytes in fetal liver [14,16]. In
previous studies, total collagen type VI, a putative marker of
mesenchymal activation, has been suggested to be an indicator of
early architectural remodeling in liver fibrosis [21–24]. Serum levels
of type VI collagen has been found to be elevated in patients with
alcoholic cirrhosis [23,24]. During fibrogenesis, the total amount of
type VI collagen is increased [14,24–26], and even though it
represents only a minor fraction of the ECM collagens, the release
to measurable products into the serum is significant, even in healthy
individuals, indicating a considerable turnover [24,27].
Several animal models for liver fibrosis have been developed,
most of them in small rodents [28], each with individual strengths
and weaknesses. These different rodent models are complemen-
tary as they represent different pathways to fibrosis, as also seen in
human disease. Bile duct ligation (BDL) in rats has been used as a
model of chronic liver injury due to its resemblance to hepatocyte
damage, hepatic stellate cell activation, and liver fibrosis observed
in human cholestatic liver diseases [1,28]. Carbon tetrachloride
(CCl4) is a hepatotoxin that causes acute liver injury and, when
given repetitively at a low dose, induces liver fibrosis. It is a highly
reproducible and robust model which is used to resemble alcoholic
and non-alcoholic steatohepatitis with the consequent fibrosis and
cirrhosis in humans [1,28].
We hypothesized that specific MMP-2 and MMP-9 mediated
degradation of type VI collagen was measurable in serum during
liver fibrogenesis. The aim of this work was to develop a novel
competitive enzyme-linked immunosorbent assay (ELISA) for
measuring MMP-2 and MMP-9 mediated turnover of type VI
collagen and to measure the neo-epitopes in two complementary
experimental models of liver fibrosis induced by BDL or CCl4.
Materials and Methods
Ethics Statement
The BDL experiments were approved by the Experimental
Animal Committee of the Danish Ministry of Justice and were
performed according to the European Standard for Good Clinical
Practice (2008/561-1450).
The CCl4 study was approved by the Ethical Committee of
Animal Experimentation of the University of Barcelona (B-NNP-
233/09) and was performed according to the criteria of the
Investigation and Ethics Committee of the Hospital Clinic
Universitari (Barcelona, Spain).
Reagents
All reagents used for the experiments were standard high-
quality chemicals from companies such as Merck (Whitehouse
Station, NJ, USA) and Sigma Aldrich (St.Louis, MO, USA). The
synthetic peptides used for monoclonal antibody production were
purchased from the Chinese Peptide Company, Beijing, China.
In vitro cleavage
Purified type VI collagen from human placenta (cat. no. ab7538,
Abcam, Cambridge, UK) was cleaved with pro-MMP-2 or pro-
MMP-9 (cat. no. 444213; 444231; Calbiochem, Merck, White-
house Station, NJ, USA). Fifty mg MMP-2 or MMP-9 was activated
with 20 ml 1 mM 4-aminophenylmercuric acetate (AMPA) in
dimethyl sulfoxide and incubated at 37uC for 3 hours. Type VI
collagen was delivered dissolved in 0.5 M acetic acid. To facilitate
MMP cleavage, the protein was dialyzed for two days to remove the
acetic acid. The liquid was filtered to remove proteins below 10 kDa
(Microcon Ultracel YM-10, cat. no. 42407, Millipore, Billerica,
MA, USA). Each MMP cleavage was performed separately by
mixing 100 mg type VI collagen and 1 mg of either MMP-2 or
MMP-9 in MMP buffer (100 mM Tris-HCl, 100 mM NaCl,
10 mM CaCl2, 2 mM Zn acetate, pH 8.0). As control, 100 mg of
collagen was mixed with MMP buffer alone. The solutions were
incubated for 24 hours at 37uC. The cleavage reaction was stopped
using 50 mM ethylenediaminetetraacetic acid (EDTA) to a final
concentration of 1 mM. Cleavage was verified by visualization using
the SilverXpressH Silver Staining Kit (cat. no. LC6100, Invitrogen,
Carlsbad, Ca, USA) according to the manufacturer’s instructions.
Pepsin cleavage was performed by mixing 100 mg type IV
collagen and 1 mg of pepsin in pepsin buffer (0.2 M sodium acetate
buffer, pH 4.0). The resultant enzyme/protein mixture was
incubated at 37uC for 2 hours. At the designated time, 2 M Trizma
Base was added to adjust pH to neutral to stop the reactions.
Peptide identification
Peptide fragments in the in vitro cleaved samples were identified
using liquid chromatography (LC) coupled to electrospray
ionization (ESI) tandem mass spectrometry (LC-MS/MS). LC-
MS samples were ultra-filtrated to remove proteins above 10 kDa,
the pH was adjusted to 2.0 using formic acid, and a 4 ml sample
was analyzed by LC-MS/MS. LC was performed on a
nanoACQUITY UPLC BEH C18 column (Waters, Milford,
MA, USA) using a formic acid/acetonitril gradient. MS and
MS/MS were performed on a Synapt High Definition Mass
Spectrometry quadruple time of flight MS (QUAD-TOF; Waters,
Milford, MA, USA), with an acquisition range of 350–1600 m/z
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in MS and 50–2000 m/z, in MS/MS. The software ‘‘ProteinLynx
Global SERVER (PLGS)’’ (Waters, Milford, MA, USA) was used
to analyze spectra and generate peak lists. To identify peptides,
MS and MS/MS data was searched against a type VI collagen
(FASTA) protein database using the Mascot 2.2 (Matrix Science,
Boston, MA, USA) software with the ESI-QUAD-TOF settings
and carbamidomethyl (C), oxidation of methionine (M), oxidation
of lysine (K) and oxidation of proline (P) as variable modifications.
The six amino acids in the N- or C-terminal of the peptides
identified by MS were regarded as a neo-epitope generated by the
protease in question. All protease-generated sequences were
analyzed for homology and distance to other cleavage sites and
tested for homology using NPS@: network protein sequence
analysis (Combet C, Blanchet C, Geourjon C, Deleage G.
NPS@:network protein sequence analysis. Trends Biochem Sci
2000; 25: 147–50).
Peptide conjugation
The peptide conjugation was performed using the Maleidide
Activated Immunogen Conjugation Kit (Sigma-Aldrich, MO,
USA). Briefly, the cysteine-containing immunogenic neo-epitope
(YRGPEGPQGP-GGC, 400 ml peptide at 5 mg/ml) with one free
sulfhydryl (-SH) group was mixed in conjugation buffer with the
maleimide-activated ovalbumin (OVA) (180 ml OVA at 10 mg/
ml) as a carrier protein with an available maleimide group that
could react with sulfhydryl-containing peptides and incubated for
2 hours at room temperature. Conjugated products were cleared
of EDTA and sodium azide by desalting or dialysis for two days.
For the biotin-conjugated peptides, the biotin-conjugated lysine
was added in the solid-phase peptide synthesis procedure.
Monoclonal antibody development
4–6 weeks-old Balb/C mice were immunized subcutaneously
with about 200 ml emulsified antigen and 50 mg of the neo-epitope
CO6-MMP (YRGPEGPQGP-GGC-OVA). Consecutive immuni-
zations were performed at 2-week intervals until stable sera titer
levels were reached in Freund’s incomplete adjuvant. Blood samples
were collected from the 2nd immunization. At each blood sampling,
the serum titer was determined and the mouse with highest anti-
serum titer was selected for fusion. After the 4th immunization, this
mouse was rested for 1 month and then boosted intravenously with
50 mg CO6-MMP in 100 ml 0.9% sodium chloride solution three
days before isolation of the spleen for cell fusion.
Fusion and antibody screening
The fusion procedure performed as described by Gefter et al
[29]. Briefly, mouse spleen cells were fused with SP2/0 myeloma
fusion partner cells. The hybridoma cells were cloned using a
semi-solid medium method and transferred into 96-well microtiter
plates for further growth and incubated in a CO2-incubater.
Standard limited dilution was used to promote monoclonal
growth. Supernatants were screened using an indirect ELISA
with streptavidin-coated microtitre plates and YRGPEGPQGP-K-
Biotin as a capture peptide.
Characterization of clones
Native reactivity and peptide binding of the monoclonal
antibodies was evaluated by displacement of native samples
(human/rat/mouse serum, plasma and urine) in a preliminary
ELISA using 10 ng/mL biotinylated peptide coater on a
streptavidin-coated microtitre plate and the supernatant from
the growing monoclonal hybridoma. Specificities of the clones to a
free peptide (YRGPEGPQGP), a non-sense peptide, and an
elongated peptide (GYRGPEGPQG) were tested. Isotyping of the
monoclonal antibodies was performed using the Clonotyping
System-HRP kit, cat. no. 5300-05 (Southern Biotech, Birming-
ham, AL, USA). The selected clones were purified using protein G
columns according to manufacturer’s instructions (GE Healthcare
Life Science, Little Chalfont, Buckinghamshire, UK). Selected
monoclonal antibodies were labeled with horseradish peroxidase
(HRP) using the Lightning link HRP labeling kit according to the
instructions of the manufacturer (Innovabioscience, Babraham,
Cambridge, UK).
CO6-MMP ELISA methodology
In preliminary experiments, we optimized the reagents, their
concentrations and the incubation periods by performing several
checkerboard analyses. The CO6-MMP ELISA was developed as
follows: A 96-well streptavidin plate was coated with biotinylated
synthetic peptide YRGPEGPQGP-K-Biotin dissolved in assay
buffer (25 mM Tris, 1% BSA, 0.1% Tween-20, pH 7.4) and
incubated 30 minutes at 20uC. Twenty ml of peptide calibrator or
sample were added to appropriate wells, followed by 100 mL of
conjugated monoclonal antibody and incubated 1 hour at 20uC.
Finally, 100 mL tetramethylbenzinidine (TMB) (Kem-En-Tec cat.
no. 438OH) was added and the plate was incubated 15 minutes at
20uC in the dark. All the above incubation steps included shaking
at 300 rpm. After each incubation step the plate was washed five
times in washing buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The
TMB reaction was stopped by adding 100 ml stopping solution
(1% HCL) and measured spectrophotometrically at 450 nm with
650 nm as the reference. A standard curve was performed by
serial dilution of the CO6-MMP peptide and plotted using a 4-
parametric mathematical fit model. Standard concentrations were
0, 0.39, 7.8, 15.6, 31.3, 62.5, 125 250 ng/mL.
Technical evaluation
From 2-fold dilutions of pooled serum and plasma samples,
linearity was calculated as a percentage of recovery of the 100%
sample. The lower detection limit (LDL) was calculated from 21
determinations of the lowest standard (the zero standard) and
calculated as the mean +3x standard deviation. The inter- and
intra-assay variation was determined by 10 independent runs of 5
QC samples, with each run consisting of two replicas of double
determinations of the samples. Finally, for each assay, a master
calibrator prepared from synthetic peptides accurately quantified
by amino acid analysis was used for calibration purposes.
The analyte stability was determined for six serum samples
(three rat and three human) for 10 freeze and thaw cycles.
ELISA characterization
The developed CO6-MMP ELISA was evaluated using 20 ml of
the cleavage-samples: type VI collagen, type VI collagen cleaved
with MMP-2, type VI collagen cleaved with MMP-9 described
under ‘‘In vitro cleavage’’. The negative control was in vitro cleaved
type VI collagen with fibroblast activation protein (FAP). Cross-
reactivity was tested using intact or in vitro cleaved type I or IV
collagen using 20 mL peptide solution of 1000 ng/mL for each test
in the assay. Neo-epitope specificity was tested using cleaved (by
either MMP-2 or MMP-9) and non-cleaved type VI collagen and
by an elongated CO6-MMP amino acid sequence (GYRG-
PEGPQG).
Bile duct ligation
A total of 40 female Sprague-Dawley rats aged 6 months were
housed at the animal research facilities at Nordic Bioscience,
A Collagen Type VI Fragment as Fibrosis Biomarker
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Denmark. The rats were kept in standard type III-H cages at 18–
22uC with bedding and nest material (Altromin 1324; Altromin,
Lage, Germany) and water ad libitum. Rats were kept under
conditions of a 12-hour light: dark cycle. Experiments began after
1 week of acclimatization. Bile duct ligation (BDL) was performed
in anaesthetized rats by ligation of the bile duct in two places and
dissection between the ligations in an open-surgery procedure. In
sham-operated rats, the abdomen was closed without BDL. BDL-
or sham-operated rats were sacrificed after 2 or 4 weeks.
CCl4 inhalation
The study included 52 3-months old male Wistar rats treated
with CCl4 and 28 Wistar control rats (Charles-River, Saint Aubin
les Elseuf, France). Complete details of the study are described
elsewhere (Segovia-Silvestre T et al.). Liver damage was induced
as previously described [30], and in short included administration
by inhalation of CCl4 twice weekly. Phenobarbital (0.3 g/l) was
added to the drinking water. Animals were stratified into groups
receiving 8, 12, 16 or 20 weeks of CCl4 (n = 13 for CCl4; n = 7
control for each group). Control rats received Phenobarbital only.
Four animals from the CCl4 groups died during the study. After
the stated weeks of CCl4 administration the rats were weighed,
anesthetized with pentobarbital (50 mg/kg) and terminated by
decapitation.
Blood and tissue sampling
Blood samples were taken under light CO2/O2 anesthesia at
baseline and at termination from the retro-orbital sinus of rats
which had fasted for at least 14 hours. The collected blood was left
for 30 min at room temperature to clot, followed by centrifugation
at 3000 g for 10 min. All clot-free liquid was transferred to new
tubes and centrifuged again at 3000 g for 10 min. The serum was
then transferred to clean tubes and stored at 280uC.
Livers were carefully dissected, weighed, fixed in 4% formal-
dehyde for a minimum of 24 hours, cut into appropriate slices and
embedded in paraffin. Liver sections (4–5 mm thick) were stained
with 0.1% Sirius Red F3B (Sigma-Aldrich, St. Louis, MO) in
saturated picric acid (Sigma-Aldrich).
Histology image analysis
Relative fibrosis area (expressed as a percentage of total liver
area) was assessed by analyzing 36 fields of Sirius Red-stained liver
sections per animal. Each field was acquired at 106magnification
[E600 microscope (Nikon) and RT-Slider SPOT digital camera
(Diagnostic Instruments, Inc., Sterling Heights, Michigan, US)].
Results were analyzed using a computerized Bioquant Life Science
morphometry system. To evaluate the relative fibrosis area, the
measured collagen area was divided by the net field area and then
multiplied by 100. Subtraction of vascular luminal area from the
total field area yielded the final calculation of the net fibrosis area.
From each animal analyzed, the amount of fibrosis as a percentage
was measured and the average value presented [31].
Immunohistochemistry
Liver sections (4 mm) were de-paraffinised, hydrated and further
peroxidase activity was blocked with the addition of 0.4% hydrogen
peroxide. Sections were then incubated with a polyclonal antibody
against type VI collagen (1:100; Abcam, Cambridge, UK). Sections
were then rinsed and the antibody binding was depicted using the
Super Sensitive Polymer-HRP IHC Detection System combined
with AEC substrate, according to the supplier’s instructions
(Biogenex, Taby, Sweden). Sections were counterstained with
Mayer’s haematoxylin. Digital photographs were taken using an
Olympus B660 microscope with 640 magnification and an
Olympus 5050-zoom digital camera (Olympus, Tokyo, Japan).
Results
In vitro cleavage and selection of peptides
High molecular bands of type VI collagen were seen by silver
staining in the in vitro control sample not exposed to proteases.
These bands were abolished in the MMP-2 and MMP-9 cleaved
samples, indicating that type VI collagen was degraded by these
proteases (data not shown). Fragments of type VI collagen cleaved
by MMP-2 or MMP-9 were identified with a statistically
significant Mascot score (p,0.05). All protease-generated neo-
epitopes were tested for homology. Among 184 MMP-2 or MMP-
9 generated neo-epitopes five sequences were selected for
immunizations since blasting showed that these sequences were
unique to type VI collagen, and conserved throughout species:
1. 573’.YRGPEGPQGPPG’584; CO6A1 generated by MMP-2
or MMP-9
2. 1164’GIGIGNADIT.’1173; CO6A3 generated by MMP-2
3. 1164’.GIGIGNADIT’1173; CO6A3 generated by MMP-2
4. 2279’GPKGGIGNRG.’2288; CO6A3 generated by MMP-9
5. 2176’.LGPMGVPGRD’2185; CO6A3 generated by MMP-9
The sequence 573’.YRGPEGPQGPPG’584 (CO6-MMP) in
the alpha 1 chain of type VI collagen generated by MMP-2 and
MMP-9 was selected consequent to the best technical performance
as the antibodies were able to distinguish between cleaved and
uncleaved type VI collagen. In addition, this sequence is 100%
homologous to human, rat and mouse (Figure 1).
Clone characterization
The antibody with the best native reactivity, affinity and
stability in the assay was chosen from the antibody-producing
clones generated after the fusion between spleen cells and
myeloma cells. The clone selected was determined to be the
IgG1 subtype.
The clone was reactive to human serum and plasma (Figure 2A),
rat serum and plasma (Figure 2B) and mouse serum (Figure 2B).
Technical evaluation
The typical standard curve is presented in Figure 2A and 2B,
showing a 4-parametric fit for the assay. The lower limit of
detection (LDL) for the assay was 0.30 ng/mL. Dilution recovery
was within 100620% (Table 1). The inter- and intra-assay
variation was a mean 4.0 and 10.1% respectively (Table 2). The
analyte stability was acceptable for 2–10x freeze/thaw cycles
within 100+/220% (Table 3).
Figure 1. Alignment. Alignment of part of type VI collagen alpha 1
sequence for mouse, rat and human.
doi:10.1371/journal.pone.0024753.g001
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ELISA characterization
To characterize the analytes detected in the assay, different
collagens were cleaved with different proteases. Both MMP-2 and
MMP-9 were able to generate the CO6-MMP fragment from
Figure 2. Assay characteristics. (A+B) ELISA run showing typical standard curves and native reactivity against (A) Human serum, plasma, (B)
Rodent: Rat serum and plasma; mouse serum, plasma and urine. Native material was run undiluted, 1:2, 1:4, and 1:8 as indicated (—).The signal is seen
as the optical density at 450 nm, subtracting the background at 650 nm, as a function of peptide concentration; (C+D) Characterization of the CO6-
MMP assay with regards to reactivity against (C) intact type VI collagen (CO6 intact), type VI collagen cleaved by MMP-2 (CO6/MMP-2), type VI
collagen cleaved by MMP-9 (CO6/MMP-9), type VI collagen cleaved by fibroblast activation protein (FAP) (CO6/FAP), elongated peptide with
extension of one amino acid at the neo-epitope site; (D) Intact type I collagen (CO1), type I collagen cleaved by MMP-2 (CO1/MMP-2), type I collagen
cleaved by MMP-9 (CO1/MMP-9), intact type IV collagen (CO4), type IV collagen cleaved by MMP-2 (CO4/MMP-2), type IV collagen cleaved by MMP-9
(CO4/MMP-9), type IV collagen cleaved by pepsin (CO4/pepsin).
doi:10.1371/journal.pone.0024753.g002
Table 1. Percentage dilution recovery for the CO6-MMP
assay.
CO6-MMP
ng/mL
HS1
44.7
HS2
36.5
RS1
9.92
RS2
14.11
Undil 100% 100% 100% 100%
Dilution 1:2 91% 87% 113% 109%
Dilution 1:4 98% 90% 110% 105%
Dilution 1:8 98% 86% 102% 96%
Dilution 1:16 93% 92% 93% 101
Mean 95% 89% 104% 103%
HS= human serum; RS = rat serum.
doi:10.1371/journal.pone.0024753.t001
Table 2. Inter- and intra-assay variation for the CO6-MMP
assays using human serum quality control samples.
CO6-MMP
Sample
Amount
(ng/mL)
Intra-assay
variability %
Inter-assay
variability %
HS1 7.6 4.5 10.1
HS2 11.7 4.8 13.3
HS3 10.5 2.9 8.7
HS4 13.1 4.3 9.4
HS5 13.8 3.7 9.2
HS6 13.3 4.2 10.5
HS7 17.8 3.8 9.8
HS8 21.3 4.3 9.9
Mean 13.6 4.1 10.1
The variation was calculated as the mean variation between 10 individual
determinations of each sample.
doi:10.1371/journal.pone.0024753.t002
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collagen type VI (Figure 2C). In contrast, the fragment was not
found in either intact or FAP-cleaved type VI collagen. Finally, no
cross-reactivity was seen between CO6-MMP and intact or
cleaved type I or IV collagens, which have high homology with
the immunization sequence of type VI collagen (Figure 2D). No
reactivity was seen against the elongated synthetic peptide, as
expected proving neo-epitope reactivity (Figure 2C).
Evaluations performed in the BDL study
During the 4 weeks, 3 of 40 rats, 2 BDL and 1 Sham, were put
down due to excessive weight loss.
Levels of CO6-MMP were significantly elevated in BDL rats
compared to sham levels at both the two-(mean BDL 29.5 ng/mL,
mean sham: 14.2 ng/mL, p= 0.0001) and four week (mean BDL:
33.0 ng/ml, mean sham: 11.8 ng/mL, p= 0.0003) termination
point (Figure 3).
By immunohistochemistry, collagen type VI deposition was
found exclusively in the venous wall of healthy rats (Figure 4B). In
contrast, in BDL rats in which marked ductal proliferation was
seen around the portal tract with the formation of multiple neo-
bile ducts, more extensive type VI collagen was found (Figure 4B).
Evaluations performed in the CCL4 study
In the CCL4 rat model, levels of CO6-MMP were significantly
elevated at all time points compared to baseline levels, except at
week 8 (week 12: mean CCl4 30.9 ng/mL, mean control 12.8 ng/
mL, p= 0.0015; week 16: mean CCl4 34.0 ng/mL, mean control
13.7 ng/mL, p= 0.0018, week 20: mean CCl4 35.3 ng/mL, mean
control 13.3 ng/mL, p= 0.0033) (Figure 5A). When CCl4- treated
rats were classified by the total amount of collagen in the liver
evaluated by histology (Sirius Red) (Figure 5B), it clearly seen that
the marker was elevated in the lowest quartile of total collagen
(quartile 1), as well as in quartiles 2–4 compared to control animals
(mean Q1: 18.1 ng/mL, p.0.03; mean Q2: 22.0 ng/mL,
p,0.05; mean Q3: 36.7 ng/mL, p,0.0001; mean Q4: 46.1 ng/
mL, p= 0.0018; mean across all controls 13.4 ng/mL). The
correlation between CO6-MMP and total collagen was highly
significant in CCl4-treated rats (p,0.0001, R2= 0.58) (Figure 5C),
however this was not seen in control rats (p = ns, R2= 0.04)
(Figure 5D).
By immunohistochemistry, collagen type VI deposition was
found exclusively in the venous wall of control rats (Figure 4D). In
contrast, in CCl4-treated rats type VI collagen was located along
the fibrotic bands (figure 4D).
Discussion
This is, to our knowledge, the first study to present the
development of an assay specific for a fragment of type VI collagen
generated by MMPs. Our main findings were: 1) A technically
robust assay was developed with monoclonal antibodies highly
specific for the CO6-MMP fragment. The assay had acceptable
inter-, and intra-assay variation, dilution recovery and a low limit
of detection; 2) CO6-MMP levels were assessed in two different
animal models of liver fibrosis: CCl4 and BDL. In both models we
found significant increased levels in liver fibrotic rats compared to
controls. In addition CO6-MMP levels were significantly corre-
lated to collagen deposition in the CCl4 model of liver fibrosis.
ECM remodeling is an essential part of tissue homeostasis.
Extensive ECM remodeling is associated with a range of
pathologies [7,8,20,26,32,33] in which fibrosis is of particular
relevance. Biochemical markers consisting of protein fragments
from pathologic tissue remodeling may be useful for diagnostic and
prognostic purposes [34]. Such an approach focusing on neo-
epitopes have primarily been useful for the arthritis and bone field
[35], and for liver fibrosis in monitoring degradation of collagen
type III [36,37].
The gelatinases MMP-2 and MMP-9 have been investigated
and documented to be highly regulated in fibrous tissue [12,13].
Cleavage of type VI collagen with these two proteases generated
several fragments. Among these CO6-MMP was chosen due to it
being unique and conversed among species. Several assays already
exist for measuring total type VI collagen in different pathologies,
using polyclonal antibodies (antibodies-online GmbH) or mono-
clonal antibodies (Uscn Life Science). Circulating levels of total
type VI collagen patients with alcoholic liver disease have been
investigated by Stickel et al [24], who found an significant elevation
in alcoholic patients compared to controls. In addition they
concluded that total collagen type VI already waselevated in early
fibrotic states and therefore seem to be an important indicator of
Table 3. Analyte stability in three rat- and three human
serum samples in 10 freeze/thaw cycles.
Analyte stability Percent recovery compared to 16freeze/thaw
Freeze/thaw cycles Human CO6-MMP Rat CO6-MMP
2x 95.2 93.6
3x 86.1 96.0
4x 102.7 92.9
5x 105.7 103.6
6x 90.1 96.7
7x 98.1 99.2
8x 92.4 95.1
9x 91.4 99.7
10x 85.2 104.6
All data are shown as percent recovery compared to day 0 or 1 freeze/thaw
cycle.
doi:10.1371/journal.pone.0024753.t003
Figure 3. CO6-MMP serum levels in BDL-rats. BDL rat liver fibrosis
model. Serum CO6-MMP was assessed in BDL and sham operated rats
at termination. Termination time points were 2 and 4 weeks after
surgery. Levels of CO6-MMP were significantly elevated in BDL rats
compared to sham levels at both the two-( mean BDL 29.5 ng/mL,
mean sham: 14.2 ng/mL, p = 0.0001) and four week mean BDL: 33.0 ng/
ml, (mean sham: 11.8 ng/mL, p = 0.0003) termination point.
doi:10.1371/journal.pone.0024753.g003
A Collagen Type VI Fragment as Fibrosis Biomarker
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24753
early fibrotic transformation [24]. These data are consistent with
our data indicating CO6-MMP is an early marker for fibrosis and
they are in alignment with the fact that collagen type VI may be a
good candidate biomarker. The CO6-MMP assay provides
additional information on protease mediated tissue destruction in
face of the total collagen markers. Such a careful deconstruction of
the information entailed in the precise analyte may prove
important to understand the processes that are leading to
increased tissue formation as well as tissue degradation, and
therefore eventually resolution of diseases. This may be assisted by
the measurement of protein degradation and protein formation, in
face of a crude measure of total protein [11,36,38]. The
competitive ELISA was technically stable with a acceptable
dilution recovery, as well as inter- and intra-variation for all
matrices tested. The highest sensitivity for the assay was observed
in the range of 4–125 ng/mL. Characterization of the selected
monoclonal antibody revealed strong reactivity towards human,
mouse and rat serum as well as the CO6-MMP peptide, strongly
suggesting that the antibody recognizes this amino acid sequence
for type VI collagen in native samples in complicated matrices.
Characterizations using the final ELISA format showed that the
recognized peptide fragment was generated by MMP-2 and
MMP-9. Furthermore, it was seen that the antibody was specific
against the neo-epitope generated in type VI collagen, as no
response was detected when type I or type IV collagen was cleaved
by MMP-2 and -9. In addition the antibody did not recognise the
elongated peptide, indicating neo-epitope specificity. The analyte
stability was very good for both human- and rat serum CO6-MMP
all recoveries within 100+/220%.
It is well-appreciated that the BDL and the CCl4 models
describe two different fibrotic processes in which increased ECM
remodelling and excessive collagen deposition are key character-
istics. The CO6-MMP was significantly related to liver fibrosis in
CCL4 treated rats treated for 12–20 weeks. Furthermore, when
rats were classified into quartiles according to the extent of fibrosis
defined as the amount of collagen in the liver, we observed that the
marker was elevated in all quartiles. The marker also correlated
highly significantly to total collagen in the livers of CCL4-treated
rats; however this was not the case in control rats, strongly
indicating liver specific pathological relevance of the neo-epitope.
In the BDL model of liver fibrosis, serum CO6-MMP was
elevated 2 and 4 weeks after BDL surgery compared to baseline
and sham levels. These data are in agreement with the previous
studies highlighting that type VI is generated during fibrogenesis
by the activated hepatic stellate cells in the liver [2,37] and that
MMP levels become elevated and unbalanced during fibrosis [1].
These data suggest that liver fibrosis is a high turnover disease, not
may nor exclusively be described as an accumulation disease with
increased collagen formation. Additionally, our data are in
alignment investigating the collagen turnover profile in fibrotic
Figure 4. Type VI collagen in the liver. (A) Sirius Red photomicrographs showing the hepatic structure in rats 4 weeks after a sham operation (1),
2 weeks after BDL (2) and 4 weeks after BDL (3) (B) Immunohistochemical analysis of type VI collagen. Type VI collagen is localized around fibrotic
structures. (C) Sirius Red photomicrographs showing the hepatic structure in rats 20 weeks after vehicle treatment (7), 8 weeks of CCl4 treatment (8),
12 weeks of CCl4 treatment (9), 16 weeks of CCl4 treatment (10) and 20 weeks of CCl4 treatment (11). (D) Immunohistochemical analysis of type VI
collagen. Type VI collagen is localized around the fibrotic bands. Original magnification640.
doi:10.1371/journal.pone.0024753.g004
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rats, which demonstrated that a MMP-9 generated fragment of
collagen type III (CO3-610) was elevated in the BDL rat model
[37]. These combined data, past and present, indicate that liver
fibroses may be a high collagen turnover disease with both
increased collagen formation [23,38] and collagen degradation.
This further emphasis the need of measuring the individual
processes, enabling discovery of pathways leading to a resolution
of the disease – by lowering tissue formation and increasing tissue
degradation transiently. Such an investigation may not be
obtained by exclusively measuring the total protein levels.
The systemic level of a biochemical marker is the result of the
activity level and number/area of affected tissues. As such, levels of
the CO6-MMP analyte are a systemic measurement of several local
events. Type VI collagen has been identified within most tissues in
different quantities [16]. In addition chronic liver diseases are
associated with co-morbidities like osteoporosis, protein and calorie
malnutrition [39], which may cause increased CO6-MMP levels
originating from secondary tissues. The increased CO6-MMP levels
in the presented two animal models may primarily derive from
fibrosis in the liver but there may be confounded by effects from
other tissues e.g. bone loss or muscular dystrophy, albeit bone only
contain minute quantities of type IV collagen [39]. The exact
contribution to the systemic pool of CO6-MMP from different
tissues, healthy and disease affected remains to be more carefully
investigated.
This study carries some limitations. One major limitation of this
study is that it is carried out in homogeneous, inbred laboratory
rats with a synchronous induction of liver disease, which that bear
little resemblance to the highly complicated presentation of clinical
description of liver fibrosis. Further investigations in clinical
settings are needed to provide more information on the usefulness
of CO6-MMP.
In conclusion, we have developed an assay using a specific
monoclonal antibody for the detection of CO6-MMP, a collagen
type VI fragment generated by MMP-2 and -9. It was
demonstrated that this marker was elevated in two pre-clinical
models of fibrosis, the BDL and the CCl4 rat model, indicating
that there is a high potential for the use of neo-epitope biomarkers
in ECM-related diseases.
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Figure 5. CO6-MMP serum levels in CCl4-treated rats. CCl4 rat liver fibrosis model: (A) Serum CO6-MMP was assessed in control rats at
termination (controls) as well as in CCl4-treated rats at termination (CCl4) at weeks 8, 12, 16, 20. Results shown are mean 6 standard error of the
mean (SEM); (B) Serum CO6-MMP in all controls pooled and CCl4 rat stratified in quartiles according to total collagen in the liver; (C) Correlations
between CO6-MMP and Sirius red in (C) CCl4 rats and in (D) control rats; Asterisks indicate statistical significance as indicated by bars. (** = p,0.05;
*** = p,0.001, ns = non-significant difference).
doi:10.1371/journal.pone.0024753.g005
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